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1. Introduction  
Gastritis is an inflammation of the stomach lining, which is fairly common and could have 
different causes. Many kind of agents may lead the stomach into an inflamed statement; in 
first place, it could be due to non-steroidal anti-inflammatory drugs (NSAID) such as aspirin, 
ibuprofen, naproxen, etc. (Fig. 1), which are used in different treatments to calm down some 
specific illness, e.g. rheumatoid arthritis; in second place, inflamation could be due to 
abrasive compounds (alcohol, acids and others) or unbalanced diets where the stomach is 
damaged by its own gastric acid; in third place, long-term physical and/or mental stress 
that result in the production of excessive amounts of stomach acid; in last place, the 
infection caused by a well-known microorganism, Helicobacter (H) pylori. When stomach 
inflammation is not treated, mainly in the latter case, the illness could end in a gastric ulcer 
or in the worst case, in gastric cancer.  
The signs and symptoms of gastritis depend on how long the problem has existed. If it 
occurs suddenly is called acute gastritis. In acute phase, superficial inflammation of the 
stomach causes the classic nausea and pain or discomfort in the upper abdomen. If it 
develops gradually is called chronic gastritis, and the symptoms might vary from those of 
acute, with a dull pain in the upper abdomen and a feeling of fullness and loss of appetite 
after a few bites of food. However, in some cases, people with chronic gastritis could not feel 
any of these symptoms. Another type is the reactive or chemical gastritis, which is defined as a 
foveolar elongation, tortuosity, and hypercellularity of the gastric surface epithelium, 
together with edema, vasodilatation, congestion of gastric lamina propria, and a paucity of 
inflammatory cells. This type of gastritis has been thought to result from duodenogastric 
bile reflux or the use of NSAIDs (Voutilainen et. al., 2002). 
Clinicians differ on classification of the less common and specific forms of gastritis, 
particularly since there are so much overlap with H. pylori in development of chronic 
gastritis and its complications. Other types of gastritis that may be diagnosed include: a) 
Acute stress gastritis, the most serious form of gastritis which usually occurs in critical ill 
patients, such as those in intensive care, where stress erosions may develop suddenly as a 
result of severe trauma or stress to the stomach lining; b) Atrophic gastritis, resulting from 
chronic gastritis which is leading to atrophy, or decrease in size and wasting away of the 
gastric lining. Gastric atrophy is the final stage of chronic gastritis and may be a precursor of 
gastric cancer; c) Superficial gastritis is a term often used to describe the initial stages of 
chronic gastritis; d) Uncommon specific forms of gastritis include granulomatous, eosiniphilic 
and lymphocytic gastritis (Sipponen & Price, 2011). 
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A recent advance in the histopathology of gastritis is the replacement of the traditional 
definition of gastric atrophy, “loss of glands”, with the new definition of gastric atrophy as 
the “loss of appropriate glands”. By this definition, intestinalized glands represent atrophy 
when the metaplastic change involves the entire length of the original glandular unit and is 
considered as metaplastic atrophy. The application of the new definition has resulted in a 
high level of agreement among gastrointestinal pathologists trained in different cultural 
contexts. As there is obvious evidence that the severity and the extent of gastric atrophy 
relate to different risk levels of gastric cancer, an international group of gastroenterologists 
and pathologists, Operative Link on Gastritis Assessment (OLGA), has developed a system of 
histologically reporting gastritis by combining the semi-quantitative scoring scale of the 
updated Sydney system (Stolte & Meining, 2001) with the new definition of gastric atrophy. 
This system expresses the extent of gastric atrophy in terms of gastritis staging (Quach et. 
al., 2011).  
Nowadays, one of the most important cases of gastritis is the infection by H. pylori strains. 
This affection was the attention focus that led to many researchers in the last years to study 
different branches of the infection process (Chenoll et. al.; 2011; Cui et. al., 2010; Ko et. al., 
2010; Wittschier et. al., 2009; Wolle & Malfertheiner, 2007). However, equal important is the 
gastritis associated to the consumption of NSAIDs since these drugs are widely used to treat 
some pains. The chronic use of NSAIDs is a common cause of gastroduodenal erosions and 
peptic ulcers resulting, in many cases, in fatal haemorrhage. Aspirin, a famous NSAID, is 
thought to cause gastric damage by both, topical irritant effects on the gastric epithelium 
and systemic effects related to suppression of mucosal prostaglandin synthesis (Fig. 1). 
Inhibition of prostaglandin synthesis reduces mucosal defenses, including mucus and 
bicarbonate secretion, blood flow, epithelial cell turnover and repair, and mucosal 
immunocyte function. NSAIDs can also interfere with the healing of preexisting lesions and 
cause a fast drop in pH within the mucus cap (Shiotani et. al., 2008). In clinical practice, a 
prostaglandin E1 derivative, misoprostol, and anti-acids, including proton pump inhibitors 
(PPIs) are routinely used for the treatment and prevention of NSAID enteropathy (Peura, 
2004). The authors previously reported the usefulness of PPIs for healing the small intestinal 
mucosal injury in experimental animal models treated with NSAID; however, there are no 
clinical data on the usefulness of PPIs in such injuries. Some studies indicated the efficacy of 
misoprostol on NSAID-induced intestinal injuries (Kuroda et. al., 2006) whereas others 
reported no effectiveness (Davies et. al., 1993). 
Among the most conventional drugs employed, PPIs such as omeprazole (OPZ) and its 
derivates are the most common although most of these drugs produce undesirable side 
effects and drug interactions (Pali-Schöll et. al., 2010, 2011). OPZ is available over-the-
counter and in inexpensive generic formulations. It is promoted as a therapy for a range of 
disease states, from mild heartburn to aggressive H. pylori gastritis (40 mg can suppress over 
80% of gastric acid secretion) being also one component of the triple-agent therapy 
(clarithromycin, amoxicillin, omeprazole) that is commonly used to eradicate H. pylori 
infection (Logan et. al., 1995). However, it is increasingly well-recognized that OPZ may also 
contribute to gastric gland toxicity, effect demonstrated by Kohler et. al. (2010) in rabbit 
gastric gland at physiologically relevant doses. Data suggest that thiol oxidation negatively 
affects intracellular proteins, which are susceptible to this chemical reaction. Authors also 
evinced that OPZ toxicity can be reversed with Vitamin C, thus providing an explanation 
for the previously observed benefits of Vitamin C co-administrated with OPZ in H. pylori 
gastritis (Kohler et. al., 2010). 
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Fig. 1. Deleterious effects of NSAIDs after administration for long periods. Normal levels of 
PGE2 helps gastric mucosa in keeping its normal characteristics. The intake of NSAIDs for 
long periods blocks the PGE2 generating unbalance in the process and situations of 
cytotoxicity. These conditions lead gastric mucosa to be unhealthy and to come into gastritis 
process. 
Anti-ulcer drugs are useful co-medications to protect the gastric mucosa from damage due to 
steroidal and non-steroidal drugs. This is especially relevant during long-term pain and anti-
inflammatory therapies, e.g. in management of rheumatoid arthritis or inflammatory bowel 
disease. Inhibition or neutralization of gastric acid with so-called anti-ulcer drugs is necessary 
to treat gastritis and peptic ulcers, e.g. drugs such as PPIs, histamine type-2 receptor 
antagonist, sucralfate, or acid neutralizers like bismuth compounds (co-prescribed to protect 
the gastric mucosa). The therapy goal is to reach gastric pH levels above 4.5 (Julapalli & 
Graham, 2005) also for children (Tofil et. al., 2008) or even above 6.0 for treating bleeding 
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peptic ulcers (Pali-Schöll et. al., 2010). Avoidance of acid is needed to stop autodigestive 
processes and support mucosal healing in the extreme environment of the gastric lumen. 
The success rate of conventional eradication of triple therapy is ca. 80% but it is constantly 
decreasing worldwide, mainly due to H. pylori antibiotic resistance (Wolle & Malfertheiner, 
2007). In addition to the cost of the treatment, this kind of therapy involves taking too many 
drugs, which might cause side effects. Before the recognition of H. pylori as the main 
ethiological agent of chronic gastritis and peptic ulcer disease, research studies were focused 
on the gastroprotective, and/or anti-acid, and/or anti-inflammatory effects of traditional 
medicinal plants and their mode of action (Borrelli & Izzo, 2000; Castillo-Juarez et. al., 2009). 
Nowadays, studies of natural products in gastritis therapy have become the main research 
area around the world. The novel therapies include natural compounds or their derivates 
co-administered whith conventional drugs. These biological and natural products include 
beneficial microorganisms and plants. 
2. Phytotherapy on gastric diseases 
Plant derivates had been employed by population to prevent different kind of diseases for 
centuries. The knowledge of plant properties was acquired by ancient civilization that 
passed down from generation to generation until today and it is known as “popular 
medicine or traditional medicine” (Al-Qura´n, 2009). The number of plants species around 
the world is infinite and medicinal plants are used to treat different kind of pathologies like 
infection, internal and external inflammatory process, dermatological, urinary/genital, 
parasitosis, hemorrhoids, blood pressure, diabetic problems, etc., although the main usage is 
against gastrointestinal and respiratory problems (Al-Qura´n, 2009; De la Cruz et. al., 2007; 
Neves et. al., 2009; Rehecho et. al., 2010). The principal way of administration is like 
beverages, infusion or decoction of different parts of the plants (root, stem, seed, rhizome, 
bark, leaf, flowers, fruit or mixtures). 
The surveys of popular medicine are useful to understanding the application of different 
plant species, the way of usage, administration and mainly their properties. In some cases, 
this kind of beverages could be effective against gastric mucosal inflammation (active 
chronic gastritis, erosive or not) and also against H. pylori, thus having antimicrobial activity 
besides anti-inflammatory effects. Asteraceae and Lamiaceae families are mainly used as 
gastroprotector, but at the same time they are also used against other diseases as wound 
healing, analgesic and anti-inflammatory. Most studies addressed the gastroprotector effect 
of different plants extracts in experimental models, e.g., gastritis (mucosal inflammation and 
mucosal infectious model), ulcers and even advanced processes like cancer model (De la 
Cruz et. al., 2007; Nergard et. al., 2004).  
Beverages are known in different cultures as “tea”. The tea is the extract obtained after 
maintaining raw plant materials in contact with hot water during certain time (the 
methodology could change if it is infusion or decoction, where decoction is an aggressive 
process of extraction). In this extract it is possible to find different compounds like 
polyphenols, flavonoids (glycosilated or not) and polysaccharides among others, that could 
interact with the mucosal barrier cells by changing the cell metabolism and modifying the 
cellular regulation; they could also display anti-H. pylori activity (Coşkun et. al., 2004; 
Formica & Regelson, 1995; Kahraman et. al., 2003; Lengsfeld et. al., 2004). Examples of some 
medicine plants against gastric disorders are presented in Table 1. 
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MEDICINAL PLANTS USED IN GASTRIC DISEASES AROUND THE WORLD 
Family 
Plant 
species 
Common
name 
Part 
used
Mode 
of 
using 
Traditional 
uses 
Country/ 
region 
References 
Acanthaceae Dicliptera 
peruviana 
(Lam.) Juss. 
Chuncho-
chuncho 
(Q) 
Leaves Infusion Stomachache Perú  
(Canta, 
Lima) 
De la Cruz et. 
al., 2007 
Asteraceae Ageratum 
conyzoides L. 
- Leaves Infusion/
Decoction
Purgative, gastric 
ulcers, wound 
healing 
West 
Africa, 
Asia and 
South 
America 
Shirwaikar et. 
al., 2003 
Carlina acaulis 
L. 
Caroelina 
(I) 
Roots Decoction Stomachache Italy 
(Valvestino
) 
Vitalini et. al., 
2009 
Tagetes elliptica 
Smith 
Chinche 
(S) 
Leaves Decoction Stomachache, 
intestinal pain, 
digestive 
Perú  
(Canta, 
Lima) 
De la Cruz et. 
al., 2007 
Tagetes filifolia 
Lag. 
Anis 
Serrano 
(S) 
Aerial 
parts 
Decoction Stomachache, 
intestinal pain  
Perú 
(Ancash) 
Hammond et. 
al., 1998 
Vernonia 
kotschyana Sch.
- Roots Decoction
, cold 
macerate 
Gastrointestinal 
disorders, gastritis 
and 
gastroduodenal 
ulcers 
Mali Nergard et. 
al., 2004 
Brassicaceae 
 
Brassica 
carinata A. 
Braun. 
Koza (ET) Leaves - Gastritis Ethiopia 
(Sheko) 
Giday et. al., 
2010 
Brassica nigra 
(L.) 
W.D.J.Koch 
- Seeds - Stomachache Ethiopia 
(Sheko) 
Giday et. al., 
2010 
Celastraceae Maytenus 
ilicifolia Mart. 
Espinheir
a santa (P)
Leaves Infusion Contraceptive, 
abortifacient, 
emenagogue, 
stomach disorders 
 
Argentina, 
Brazil, 
Paraguay 
Hatsuko 
Baggio et. al., 
2007 
Compositae Achillea 
tomentosa L. 
Mifoil (E) Aerial 
parts 
Infusion Stomachache Jordan 
(Showbak) 
Al-Qura’n et. 
al., 2009  
Croton cajucara 
Benth 
Sacaca (P) Leaves 
barks 
Infusion Antiulcerogenic, 
gastrointestinal 
disorders 
Brazil Hiruma-Lima 
et. .al., 2000 
Euphorbiacea
e 
Jatropha isabelli 
Muell. 
Yagua 
rova (G) 
Rhi-
zome 
Infusion/
Decoction
Gastroprotective Paraguay, 
Argentina 
Pertino et. al., 
2007 
Geraniaceae 
 
Geranium 
molle L. 
Erva de S. 
Roberto, 
Bico de 
pinga 
amor (P) 
Aerial 
parts, 
roots 
- Stomach acidity 
and stomachache, 
cancer treatment, 
uterus 
inflammation 
Portugal  
(Trás-os-
Montes) 
Neves et. al., 
2009 
Pelargonium 
sidoides DC 
Umckaloa
bo (A) 
Roots - Antimicrobial 
effects 
Southern 
Africa 
Wittschier et. 
al., 2007 
Pelargonium 
roseum 
(Andrews) 
Geranio 
(S) 
Leaves Infusion/
decoction
Digestive, 
carminative, 
 gastritis, 
Perú (Nor-
Yauyos) 
Elmann et. al. 
2010; Rehecho 
et. al., 2010 
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MEDICINAL PLANTS USED IN GASTRIC DISEASES AROUND THE WORLD 
Family 
Plant 
species 
Common
name 
Part 
used
Mode 
of 
using 
Traditional 
uses 
Country/ 
region 
References 
W.T.Aiton amigdalitis,  
hemorrhagias of 
the gastro-
intestinal tube, 
others 
Krameriaceae Krameria 
lappacea 
(dombey) 
Burdet et B. 
Simpson 
Ratanya 
or Ratiñay 
(Q) 
Roots, 
stems 
Decoction Diarrhea, 
inflammation, 
treatment of 
stomach cancer 
Perú 
(Ancash) 
Hammond et. 
al., 1998; De la 
Cruz et. al., 
2007 
Lamiaceae  
 
 
 
 
 
 
 
 
 
Lamiaceae 
 
 
Glechoma 
hederacea L. 
Malvela, 
redondinh
a (P) 
Aerial 
parts 
- Cough, stomach 
pain, gastritis and 
acidity, diarrhoea, 
renal problems, 
others 
Portugal  
(Trás-os-
Montes) 
Neves et. al., 
2009 
Melissa 
officinalis L. 
Cidreira 
(P) 
Aerial 
parts 
- Intestinal gases 
and pain, digestion 
and bile 
stimulation, 
stomachache and 
gastritis, others. 
 
Portugal  
(Trás-os-
Montes) 
Neves et. al., 
2009 
Mentha 
piperita L. 
Hortelão, 
Piperita, 
Pimenta 
(P); Menta 
(S) 
Green 
leaves 
Infusion  Digestive and 
antiflatulence to 
relieve gastritis, 
dyspepsia and 
biliar disorders, 
analgesic, rheuma, 
others 
Portugal  
(Trás-os-
Montes); 
Perú (Nor-
Yauyos) 
Neves et. al., 
2009; Rehecho 
et. al., 2010 
Minthostachys 
mollis (Kunth.) 
Griseb.  
Muña (S) Leaves Infusion Digestive, 
carminative, 
emolient ,diuretic, 
to treat diarrhea, 
gastritis and colics, 
others 
Perú  
(Nor-
Yauyos) 
Rehecho et. 
al., 2010; 
Schmidt-
Lebuhn, 2008; 
De la Cruz et. 
al., 2007 
Marrubium 
vulgare L. 
Mala 
mujer (S) 
Leaves, 
stems 
Infusion Stomachache Perú  
(Canta, 
Lima) 
De la Cruz et. 
al., 2007 
Ocimun suave 
Willd 
Olomora 
(A) 
Leaves Oil Gastric ulcers, anti-
cathartic, fever, 
stomachache 
Tropical 
Asia ; west 
and east 
Africa  
Tan et. al., 
2002 
Fabaceae  Glycyrrhiza 
glabra L. 
Liquorice 
(E) 
Roots Syrup Diuretic, gastric 
ulcer, expectorant 
Mediterran
ean region, 
Asia Minor 
and Middle 
East 
Al-Qura’n et. 
al., 2009; 
Wittschier et. 
al., 2009 
Malvaceae  Althaea rosea
(L.) Cav.  
Rose 
mallow (E); 
Alteia (P) 
Aerial 
parts, 
roots 
Infusion  Abdominal 
inflammation, 
cough, colitis and 
Jordan 
(Showbak); 
Portugal  
Al-Qura’n et. 
al., 2009; 
Neves et. al., 
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MEDICINAL PLANTS USED IN GASTRIC DISEASES AROUND THE WORLD 
Family 
Plant 
species 
Common
name 
Part 
used
Mode 
of 
using 
Traditional 
uses 
Country/ 
region 
References 
gastritis, pleura 
infection, dental 
growth and 
development, 
others 
(Trás-os-
Montes) 
2009 
Abelmoschus 
esculentus (L.) 
Moench. 
Okra Fruits Fresh 
fruits 
Cholesterol 
reduction 
hypoglycemic, 
gastric irritation 
Africa, 
Asia and 
America 
Lengsfeld et. 
al., 2004 
Papaveraceae Papaver rhoeas 
L. 
Poppy(E) Leaves, 
stems 
Decoction Antidysenteric, 
antispasmodic 
Jordan 
(Showbak) 
Al-Qura’n et. 
al., 2009;  
Piperaceae Peperomia 
galioides HBK 
var gladioides 
Congona 
(Q) 
Aerial 
parts 
Crushed/
Juice 
Wounds healing, 
juice is swallowed 
to treat gastric 
ulcers 
Perú 
(Ancash) 
Hammond et 
al., 1998 
Poaceae Cynodon 
dactylon L. 
Grama (P) Dried 
roots 
- Diuretic, 
depurative, gastric 
inflammation 
Portugal  
(Trás-os-
Montes) 
Neves et. al., 
2009 
Polygalaceae  Polígala 
paniculata 
Linneau 
Barba-de-
são-
joão,vasso
urinha 
branca or 
mimosa 
(P) 
Aerial 
parts 
- Gastrprotector , 
asthma, bonchitis, 
stomach pain, 
diarrhea, anti-
inflammatory, 
anti-spasmodic  
Brazilian 
Atlantic 
coast 
Rocha Lapa et. 
al., 2007 
Punicaceae Punica 
granatum L.  
Pomegran
ate (E) 
Fruits Fresh 
fruits 
Ulcer, hepatic 
damage, tonic 
fever, heart and 
gastric diseases, 
others 
Europe, 
Indo-
China, 
South 
Africa 
Ajaikumar et. 
al., 2005 
Rosaceae Sarcopetertum 
spinosum (L.) 
Spach. 
Thorny 
burnet (E)
Roots, 
fruits 
Soaking Renal calculi, 
antidiabetic, 
gastric diseases  
Jordan 
(Showbak) 
Al-Qura’n et. 
al., 2009;  
Scrophulariac
eae 
 
Calceolaria 
bicolor Ruiz & 
Pav. 
Zapatito 
or globo-
globo (S) 
Leaves, 
flowers
Infusion Stomachache Perú  
(Canta, 
Lima) 
De la Cruz et. 
al., 2007 
Calceolaria 
lobata Cav. 
Globo-
globo (S) 
Leaves, 
flowers
Infusion Stomachache Perú 
(Canta, 
Lima) 
De la Cruz et. 
al., 2007 
Solanaceae Hyoscyamus 
aureus L. 
Handbane 
(E) 
Aerial 
parts 
Decoction Narcotic, hypnotic, 
stomachache 
Jordan 
(Showbak) 
Al-Qura’n et. 
al., 2009  
Verbenaceae  Lippia siodides 
Cham. 
- Aerial 
parts 
Hydro-
alcoholic 
tincture 
Wounds, mycoses, 
stomachache 
Northeast 
Brazil 
Barros 
Monteiro et. 
al., 2007 
Lippia 
integrifolia 
(Gris.) Hieron.
Incayuyo 
(S) 
Aerial 
parts 
Infusion/ 
Decoction
Dyspepsia, 
diuretic, cough 
treatment, 
indigestion, 
stomachache  
 
Central 
and 
Northwest 
Argentina 
Gorzalczany 
et. al., 2008 
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MEDICINAL PLANTS USED IN GASTRIC DISEASES AROUND THE WORLD 
Family 
Plant 
species 
Common
name 
Part 
used
Mode 
of 
using 
Traditional 
uses 
Country/ 
region 
References 
Vochyslaceae Vochysla 
tucanorum 
Pau-
tucano or 
pau-doce 
(P) 
Leaves, 
barks 
Infusion Stomach 
inflammation, 
asthma, 
pulmonary 
congestion 
South 
America 
Camargo 
Gomes et al., 
2009 
Zingiberaceae  Amomum 
subulatum 
Roxb. N. O. 
Heel 
kalan, Bari 
ilaichi (I) 
Fruits Infusion Stomacheache, 
digestive, anti-
emetic, carminative
India  Jafri et al., 
2001 
Table 1. Medicinal plants used for treatment gastric disorders according to native 
population of different areas around the world. The names of the species are given 
according to the regional language: (Q) quechua, an indigenous language from Bolivia, Perú, 
north-western of Argentina and Chile; (I) Italian; (S) Spanish; (E) English; (ET) Ethiopian; (P) 
Portuguese; and (G) Guaraní, a native language from Paraguay, south-western of Brazil and 
north-eastern of Argentina. 
2.1 Effects of phenolic compounds of medicinal plants on gastritis 
Gastritis troubles led to researchers to study the gastric mucosa in different animal model 
(rat, mouse, pig, rabbit, among others) where mucosal damage was induced by either 
chemical compounds (aspirin, HCl, ethanol, acetic acid, ibuprofen and more), stress 
(hypothermia), pylorus ligation or by microbiological agents (H. pylori). These in vivo 
experimental assays are useful to resemble gastric diseases as gastritis or ulcers, and help us 
to understand the way of action of natural compounds or complex extract of medicinal 
plants. These compounds acts at different levels, e.g., immune mucosal response, H+/K+ 
pumping block, histamine release from mast cell, mucus wall structure, or prostaglandin 
(PG), myeloperoxidase (MPO) and nitric oxide (NO) regulation. Results obtained in the 
framemark of pre-clinical studies may be extrapolated to human cases (Elseweidy et. al., 
2008; Hatsuko Baggio et. al., 2007; Wittschier et. al., 2007). 
Flavonoids are phenolic compounds widely distributed in a wide variety of edible plants 
including leafy vegetables, fruits (strawbery, apple, etc.) and beverages (tea, red wine, beer, 
etc.). They have been reported to exert multiple biological effects, including antiviral, 
antithrombotic, anti-ischemic, anti-inflammatory, antihistaminic, antioxidant and free-
radical scavenging abilities (Kahraman et. al., 2003). The phenolic compounds, widely 
distributed in plants, are the major compounds associated to human health and beneficial 
effects on gastritis, ulcer and cancer. The gastroprotective effect seems to be related to 
increase in endogenous PG, reduction in histamine secretion, scavenging oxygen-derived 
free radicals and even to gastric mucus stimulation (Rocha Lapa et. al., 2007; Tan et. al., 
2002). The importance of such effects is to assure the gastric mucosal integrity by a dynamic 
balance and homeostasis between epithelial cell renewal and cellular apoptosis. In normal 
mammalian stomach, gastric mucosal cells have a rapid rate of turnover, being entirely 
replaced within 3–5 days as the result of rapid proliferation of progenitor cells at the 
isthmus and rapid cell death at the gastric surface (Park et. al., 2004).  
However, treatment of gastric trouble with phenolic compounds is not always beneficial to 
gastritis condition. On one hand, the main effect is associated to anti-inflammatory response 
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due to PG and NO inhibition; on the other hand, PG is responsible for the integrity of gastric 
mucosa through activation of a cascade of mechanisms that include inhibition of gastric acid 
secretion, stimulation of mucus-bicarbonate secretion and apoptosis, as well as modulation 
of the blood flow (Atay et. al., 2000) while NO is also involved in regulation of gastric 
motility, mucus and acid secretion (Uchida et. al., 2001). 
Different medicinal plants gave good results in gastric trouble treatments, effects that were 
related to the anti-inflammatory and antioxidant activity of phenolic compounds. As an 
example, the ethanol extract of Ageratum conyzoides L. (Asteraceae) exhibited DPPH (2,2-
diphenyl-1-picrylhydrazyl, and stable radical) scavenging activity and NO generation in a 
concentration dependent manner, displaying greater gastroprotector effect (at dose levels of 
500 and 750 mg/kg) than conventional drugs as misoprostol and famotidine, which are 
used in gastritis treatment (Shirwaikar et. al., 2003). Flavonoids including quercetin 
(3,5,7,3’,4’-pentahydroxyflavone) and catechins (belonging to the flavan-3-ols group) were 
identified in Maytenus ilicifolia Mart. (Celastraceae) named in Brazil as “espinheira santa”; 
these compounds are related to antiulcerogenic activity and/or inhibition of gastric acid 
secretion, both in vivo and in vitro models. The effective gastric protection of M. ilicifolia 
flavonoid-rich fraction seems to be related to inhibition of gastric acid secretion 
(cyclooxygenase-prostaglandin system) rather than to glutathione and mucus regulation. 
The arabinogalactan fraction of this plant proved to be more effective than the flavonoid-
rich fraction (Hatsuko Baggio et. al., 2007).  
Quercetin is a common flavonoid distributed in a broad variety of vegetables, fruits and 
beverages as tea, red wine, beer, etc. It is known for its vasoactive properties but it also 
prevented gastric mucosal ulcers induced in rats by the administration of ethanol. The 
flavonoid prevented the increase of MPO activity (associated to this experimental model) 
thus protecting gastric mucosa from the deleterious effects of activated neutrophil 
infiltration (Kahraman et. al., 2003). Besides, its antioxidant property may reduce the lipid 
peroxidation and protein carbonyl compounds, increasing the superoxide dismutase activity 
which may play a role on gastric inflammation (Coskun et. al., 2004; Kahraman et. al., 2003, 
as cited in Serrano et. al., 1999). A novel natural product isolated from the Scutellaria 
baicalensis Georgi (Lamiaceae) roots (traditionally used against inflammation related 
diseases) is Wogonin (5,7-dihydroxy-8-methoxyflavone) which displayed similar effects of 
rebamipide (a well-known drug prescribed clinically for the treatment of gastritis and 
gastric ulcer) in the prevention of alcohol stomach injury (Park et. al., 2004). The target of 
these compounds would be the araquidonic acid metabolism including suppression of 5-
lipooxigenase (LOX) and induction of ciclooxigenase-2 (COX-2), thus displaying strong anti-
inflammatory activity on alcohol-related gastric disease (Cellotti & Laufer, 2001). 
Besides phenolic compounds, terpenes from essential oil (EO) were also tested with 
outstanding results. Solidagenone is a labdane diterpene synthesized in rhizomes of Solidago 
chilensis Meyen (Asteraceae); it was used to treat symptomatologies related to inflammation. 
Solidagenone and its derivative solidagen-6ǃ-ol on the HCl/ethanol-induced gastric lesions 
in mice was assessed at 100 mg/kg, being as active as lansoprazole at 20 mg/kg, but the 
mode of action remains to be elucidated (Schmeda-Hirschmann et. al., 2002). Oral pre-
treatment of mice with EO from Lippia sidoides Cham. (Verbenaceae) caused inhibition of 
gastric lesions but did not stimulate mucus production; similar results were obtained with 
OPZ. Consequently, the gastroprotective mechanism induced by the Lippia sidoides EO 
would not be related with cytoprotection (Barros Monteiro et. al., 2007). The EO of Croton 
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sonderianus (Muell. Arg), Amomum sublatum (Jafri et. al., 2001), Nigela sativa (El-Abhar et. al., 
2002) and Croton cajucara (Hiruma-Lima et. al., 2000) also showed protective activities on 
gastric mucosa. On the other hand, Anethole, a constituent present in many essential oils 
and its derivatives 1-hydroxy-1-(4-methoxyphenyl)-propane and 1-hydroxy-1-(4-
methoxyphenyl)-2-m-chlorobenzoyl-propane seemed to have gastroprotector effect against 
ethanol-induced gastric lesions without modifying the mucus secretion (Freire et. al., 2005).  
OPZ is an effective inhibitor of leukocyte infiltration, over-expression of adhesion 
molecules, IL-1a, and TNF-α production. When rats received OPZ, the lipid-peroxidation 
(expressed in terms of malondialdehyde and NO) decreased and pepsinogen secretion is 
stimulated, so its therapeutic effect could be related to its antioxidant property. On the other 
hand, authors compare the OPZ with natural compounds as curcuminoids; curcuminoids 
are isolated from dried roots of turmeric (Curcuma longa; Zingiberaceae) and when are 
administered in rats with induced gastritis the serum NO level tend to decrease compared 
to control group (without treatment). This effect could be associated to some mechanisms: 
Reduction of iNOS expression or scavenging of NO molecule. The free radicals scavenging 
properties of curcuminoids and maintaining cellular glutathione (GSH) stores in glandular 
stomach are factors acting to inhibit lipid peroxidation. Although curcuminoids significantly 
decreased serum gastrin level, it failed to stimulate pepsinogen release from chief cells 
(Elseweidy et. al., 2008).  
2.2 Effectiveness of plants glycoside derivate compounds on H. pylori infection  
Phenolic compounds as flavonoids and their derivates have also antimicrobial effects as it 
was demonstrated in cases of H. pylori infection (Atherton, 2006; Wittschier et. al., 2007, as 
cited in Warren and Marhall, 1983). Thus, catechins the main component of green tea, may 
inhibit the H. pylori urease (Matsubara et. al., 2003) and also when it is used together with 
sucralfate in Mongolian gerbils (Takabayashi et. al., 2004). The green tea has confirmed its 
bactericidal and bacteriostatic effects in vitro assays while in vivo studies demonstrated that 
its consumption when is taken before infection prevents gastric mucosal inflammation, and 
when is taken after infection diminishes the magnitude of gastritis. On the other hand, 
Castillo-Juarez et. al., (2009) studied the anti-H. pylori activity of 53 plants used in Mexican 
traditional medicine for gastrointestinal disorders. On the whole, about 77% of the assayed 
plants are active, having from moderate to strong antibacterial activity against H. pylori. 
Since some of these medicinal plants are used as condiments or food ingredients (e.g., 
Ocimum basiliscum, Persea americana, Lippia berlandieri, Teloxys graveolens), it seems that a 
frequent consumption could have a preventive effect in controlling the H. pylori population 
on infected people. 
It has been suggested that the best way to prevent H. pylori infections is to eliminate the 
pathogen from its most common habitat, the gastric mucus layer but nowadays research is 
focused on a new property of some natural compounds, i.e., the anti-H. pylori adhesion. The 
adhesive process of H. pylori is based on bacterial adhesins located on its outer cell wall, 
which are responsible for interaction with mucosal glycoproteins and epithelial mucins; in 
this way the infection is established. Certain compounds, e.g. polysaccharides, may interact 
with the bacterial adhesins before adhesin-mucin adhesion avoiding the infection process. 
Studies on the complex nature of these adhesins are reported by Evans & Evans, (2000), 
Kusters et. al. (2006), and Wittschier et. al. (2009). 
Adhesion to epithelial cells has been recognized as an essential step of the infectious process 
for virtually all bacterial pathogens and therefore many efforts are aimed to develop anti-
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adhesion therapy. Sialyllactose (NeuAc[K2-3]Gal[L1-4]Glc), an inhibitor of the sialic acid-
specifc adhesin of H. pylori, significantly reduced the load of the bacteria in monkeys 
(Burger et. al., 2000, as cited in Glaser, 1997). Accordingly, it would seem appropriate to 
target such therapy against H. pylori toward its association with the mucus before the 
pathogen adheres to the underlying epithelial cells and causes disease. However, the bulk 
production of oligosaccharides specific for the H. pylori lectins as anti-adhesion therapeutic 
agents is still a problem to be solved. As an alternative approach, dietary inhibitors might be 
the solution for certain infections, e.g. the inhibition of sialic acid-specific adhesion of H. 
pylori to human gastric mucus and to human erythrocytes by cranberry juice (Burger et. al., 
2000). Another example is the root extracts of Pelargonium sidoides DC (Geraniaceae) a 
medicinal specie used to treat acute respiratory infections, which contains a polysaccharide 
fraction, EPs 7630, with anti-adhesive activity against H. pylori (Wittschier et. al., 2007). The 
roots of Glycyrrhzia glabra L. contain a raw polysaccharide fraction mainly composed of 
arabinose, galactose, glucose and glucuronic acid, which interacts with the outer-membrane 
surface adhesins of H. pylori avoiding its adhesion to mucus (Wittschier et. al., 2009). 
Authors consider this anti-adhesive effect an advantage to prevent re-infection by H. pylori 
after antibiotic eradication therapy. 
These beneficial effects lead us to conclude that natural inhibitors of bacterial growth and 
inflammation may offer alternatives to antibiotic therapy for bacterial eradication and may 
be used as supplements to conventional eradication therapy in populations at high risk for 
gastric cancer (Stoicov et. al., 2009). 
3. Lactic acid bacteria in gastritis 
Lactic acid bacteria (LAB) are a group of Gram-positive, non-sporulating bacteria that 
include species of Lactobacillus, Leuconostoc, Pediococcus and Streptococcus. Dietary LAB refers 
to those species and strains that are used in food- and feed-fermentation processes. The term 
LAB is a group of organisms that are defined by their ability to produce a common end 
product, lactic acid, from the fermentation of sugar. LABs have limited biosynthetic abilities, 
and require pre-formed amino acids, B vitamins, purines, pyrimidines and, usually, a sugar 
as a carbon and energy source. LABs occupy a range of niches, including milk, plant 
surfaces and the oral cavity, gastrointestinal tract and vagina of vertebrates. Since ancient 
times, dietary LABs have been used to ferment a range of raw materials such as milk, which 
is used to produce cheese (species of Lactococcus) and yoghurts (species of Streptococcus and 
Lactobacillus). Consumed for centuries, LABs have a long and safe association with humans 
and their food (Wells & Mercenier, 2008). 
Probiotic foods containing LAB have been proposed as a natural alternative to improve the 
general health status, preventing various gastrointestinal disorders such as gastric ulcers 
and inflammation related to H. pylori infection, gastrointestinal infections (Lebeer et. al., 
2010) or antibiotic-associated diarrhea (Chen et. al., 2009; Gill & Guarner, 2004; Penner et. al., 
2005) providing beneficial effects to the host by modulating immune functions, e.g. systemic 
cytokine production (Borchers et. al., 2009). 
Different LAB species were tested in gastritis models mainly in treatment of H. pylori 
infection. Some reports suggested that certain species of exogenous lactobacilli have 
inhibitory effects on gastric infection (Cui et. al., 2010; Ryan et. al., 2008), e.g., Lactobacillus 
(L.) reuteri ATCC 55730 displayed ability to colonize the gastrointestinal tract and at the 
same time, to generate an inmune response when it was administered to human volunteers. 
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After administration, L. reuteri was detected by fluorescence in situ hybridization (FISH) in 
stomach and duodenum in some volunteers. According to these results it was suggested 
that stimulation of T-helper cells in human ileum could be a central mechanism of symbiosis 
for improving the health of the host gut (Valeur et. al., 2004). Similar results were obtained 
with a commercial product (Lacidofil®) containing L. acidophilus R0052 and L. rhamnosus 
R0011 (Johnson-Henry et. al., 2004). The probiotic mixture exhibits bactericidal activity in a 
dose-dependent manner by altering normal H. pylori morphology and thereby inhibiting its 
growth. Authors (Johnson-Henry et. al. 2004) suggested that probiotics are an attractive 
option for counteracting the effects caused by H. pylori infection for many reasons: LABs are 
able to resist acid and bile, to transiently remain under the harsh stomach conditions, and to 
competitively exclude pathogenic bacteria. In vitro studies showed that certain LAB strains 
and their cell-free cultures are able to inhibit or kill H. pylori (Michetti et. al., 1999; Sgouras 
et. al., 2005) as well as to reduce urease activity in the human gastric epithelial cells (AGS) 
by exclusion effect (Lin et. al., 2011). Likely, Ko et. al. (2010) evinced that L. casei ATCC 393-
loaded chitosan microspheres inhibited H. pylori growth in in vitro assays.  
B. bifidum CECT 7366 is also a promising microorganism against H. pylori infection. Results 
from in vitro and in vivo models (BALB/c mice) indicated that the strain partially relieves 
damage of gastric tissues caused by the pathogen and also decreases the H. pylori 
pathogenicity ratio (Chenoll et al., 2011).  
The inclusion of probiotics in a conventional therapy (triple therapy: antibiotics and PPI) for 
H. pylori eradication was also evaluated (Kim et. al., 2008). H. pylori-infected patients were 
administered with yogurt (Will yogurt) containing L. acidophilus HY2177, L. casei HY2743, 
Bifidobacterium longum HY8001 and Streptococcus thermophilus B1; at the same time, they were 
treated according to the triple therapy. As a conclusion, the addition of yogurt did not 
reduce the side-effects of the therapy but increased the H. pylori eradication rate. Similar 
results had been reported using fermented milks with L. acidophilus and L. casei (M.J. Park et. 
al., 2001). Recently, Shirasawa et. al. (2010) evinced that the probiotic strain B. bifidum BF-1 is 
able to suppress IL-8 induction by H. pylori through inhibition of the genes related to the 
NF-κB signaling pathways. Other LAB strains were also effective against H. pylori in 
gastritis cases, e.g., L. johnsonii La1 displayed a pronounced anti-inflammatory effect on H. 
pylori-associated neutrophilic and lymphocytic infiltration in animal model by reducing pro-
inflammatory chemokine levels in the gastric mucosa during the early stages of infection 
(Sgouras et. al., 2005). The markers for gastric inflammation such as prostaglandin I/II ratio 
(Sakamoto et. al., 2001) or ornithine decarboxylase activity (Linsalata et. al., 2004) also 
decreased in patients treated with probiotics, effects that persisted for several weeks after 
cessation of the treatment. Likely, Cui et. al. (2010) demonstrated that L. fermenti (CCTCC M 
206110) and L. acidophilus LC, isolated from gastric biopsy materials of patients, could 
alleviate the gastric inflammation in H. pylori-infected BALB/c mice after oral 
administration. These results would indicate that specific lactobacilli strains may colonize 
the gastric mucosa, which may be related to their capacity to survive and develop in acidic 
environments (Cats et. al., 2003; Cui et. al., 2010; Gotteland & Cruchet, 2003; Mater et. al., 
2005; Mozzi et. al., 2009; Valeur et. al., 2004; Wang et. al., 2004).  
The effect of LAB on acute gastric lesions induced by chemical agents in experimental 
models was also reported. The administration of probiotic lactobacilli as L. gasseri OLL2716, 
L. casei GG, L. paracasei subsp. paracasei NTU 101 and L. plantarum NTU 102 to rats inhibits 
the gastric mucosa injury in HCl/ethanol-induced ulcer and pyloric ligation models (Lam 
et. al., 2007; Liu et. al., 2009; Uchida & Kurakazu, 2004). 
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Researchs on the functional properties of metabolites produced in food by LAB during 
fermentation such as exopolysaccharides (EPS) increased in recent years by assigning to 
biopolymers potential beneficial effects on human health. These effects include prebiotic 
effects (Dal Bello et. al., 2001; Korakli et. al., 2002; Salazar et. al., 2009), hypocholesterolemic 
effect (Pigeon et. al., 2002) and immunomodulatory and anti-tumor activity (Chabot et. al., 
2001; Kitazawa et. al., 1998;) as well as other immune functions such as proliferation of T-
lymphocytes (Forsén et. al., 1987), activation of macrophages and induction of cytokine 
production (Kitazawa et. al., 1991, 1996). The EPS could remain attached to the cell wall 
(capsular EPS) or be excreted into the environment in the form of slime or ropy EPS and its 
structure may vary depending, mainly, on the strain (van Hijum et. al., 2006). LABs produce 
two different kinds of EPS by using distinct biosynthetic pathways. The homo-
polysaccharide (HoPS) are synthesized by extracellular glycansucrases and contain only one 
type of sugar (generally glucose) and the hetero-polysaccharide (HePS) that are assembled 
by cell wall-bound glycosyl-transferases from intracellular sugar nucleotide precursors, 
which may be constituted by 3 to 8 different monosaccharides (de Vuyst et. al., 2001). There 
are many EPS-producing LABs, e.g., L. acidophilus, L. sakei, L. delb. subsp. bulgaricus, L. 
helveticus, L. paracasei, L. pentosus, L. plantarum, L., rhamnosus, L. reuteri, L. casei, Leuconostoc 
mesenteroides and Streptococcus thermophilus although it is a strain-dependent property 
(Mozzi et. al., 2006; Ruas-Madiedo et. al., 2002).  
It is known that the EPS of LAB have many functional properties; they have effect on the 
mucosal immune system, could avoid the H. pylori adhesion to the mucus layer, and could 
make the mucus layer stronger, among others. Despite these beneficial properties, there are 
few studies in the literature concerning the protection of gastric epithelium by EPS-
producing LAB or the role they could play in the gastric injury. Ruas-Madiedo et. al. (2006) 
suggested that the biopolymers are involved in the mechanism of competitive exclusion of 
probiotics through adherence to the mucus and Nagaoka et. al. (1994) reported anti-ulcer 
effects of the cell wall polysaccharide of bifidobacteria, lactobacilli and streptococci strains, 
which were attributed to the high rhamnose content of the polymers (> 60%).  
Rodríguez et al. (2009, 2010) reported the first evidences on the beneficial effects of both the 
EPS-producing LAB strains and the biopolymer on gastritis experimental animal models 
using acetyl salicylic acid (ASA) as gastritis inductor. Authors demonstrated the 
gastroprotector effect of fermented milk with the EPS-producing strain S. thermophilus CRL 
1190 on superficial chronic gastritis in BALB/c mice as preventive and therapeutic 
treatment. Other EPS-producing strains S. thermophilus CRL 804 and CRL 638, and L. casei 
CRL 87 were also evaluated in vivo assays but with unsuccessful results. The biopolymers 
had different physical-chemical properties: S. thermophilus CRL 1190 produced a high 
molecular mass EPS (1500 kDa) composed of D-glucose and D-galactose; S. thermophilus 
CRL 638, a high EPS (1200 kDa) composed of D-glucose, D-galactose and N-
acetilglucosamine; S. thermophilus CRL 804 produced a low EPS (95 kDa) composed of D-
galactose and L-rhamnose, and at last, L. casei CRL 87 produced a low EPS (800 kDa) 
composed of D-glucose, D-galactose and L-rhamnose. The strains CRL 1190 and CRL 87 also 
produced capsular polysaccharide in addition to the slime EPS in milk and was able to form 
ropy milk cultures similar to CRL 638, while the strain CRL 804 was negative for both the 
capsular and ropy phenotypes (Mozzi et. al., 2006).  
The fermented milk with S. thermophilus CRL 1190 (FM-1190) as well as the EPS (EPS-1190) 
suspended in milk (but not in water) was the only one effective in both the therapeutic and 
preventive treatment of chronic gastritis in animal models. Results obtained were similar to 
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that of OPZ but with the advantage of not having side effects. The FM-1190 also activated 
the synthesis of mucin, which in turn led to an increase in the thickness of the mucus layer 
and in the amount of mucus of the body and antrum that were decreased after ASA 
administration. The recovery of the gastric defensive systems and the mucus-bicarbonate 
layer in animals fed FM-1190 favored the recovery of the damaged gastric mucosa. These 
evidences support previous reports obtained in rats with acute gastric damage which were 
fed with probiotic lactobacilli (Nam et. al., 2005; Lam et. al., 2007).  
The fermented milk FM-1190 and the EPS-1190 were able to modulate the gastric 
inflammatory response at the immune system level (decrease in the number of cells 
producing pro-inflammatory cytokines, INF-γ and TNF-α, and increase in the number of 
cells producing regulatory cytokines, such as IL-10). These promising results, however, can 
not be ascribed to all EPS-producing LABs because of the complexity of the phenomenon. 
The fermented milk with the strain S. thermophillus CRL 804 which produced an EPS formed 
by rhamnose and galactose did not display any anti-gastritis effect in contrast to the results 
obtained by Nagaoka et. al. (1994) with cell wall polysaccharides containing rhamnose. In 
contrast to the FM-1190, the fermented milk with S. thermophilus CRL 638 generated a great 
stomach inflammation in animal model, without gastritis induction, after 7d of feeding.  
Studies of scanning electronic microscopy (SEM) confirmed a greater secretion of gastric 
mucus after oral administration of FM-1190; they also put in evidence the presence of the 
strain CRL 1190 in the stomach at least 15 days after finishing the administration of the 
fermented milk. These confirmed previous reports concerning the ability of S. thermophilus 
strains to survive the passage through the gastrointestinal tract and to exert the beneficial 
effects on various gastrointestinal disorders (Brigidi et. al., 2003; Delorme, 2008; Guarner et. 
al., 2005; Mater et. al., 2005; Vinderola & Reinheimer, 2003). Studies performed in in vitro 
gastric system evinced a partially degradation of the EPS-1190 when subjected to this harsh 
conditions (Mozzi et. al., 2009). From results from in vivo and in vitro studies, it is assumed 
that the biopolymer may still exert its beneficial properties in the stomach even partially 
degraded.  
Several studies reported that high molecular mass-polysaccharides of different sources 
(herbs, marine microalgae and fungi) have anti-ulcer, anti-inflammatory or inmuno-
stimulatory effects related to anti-secretory activity of acid and pepsin, inmuno-stimulation, 
stimulation of gastric mucus, increase in gastric prostaglandin levels and partially 
suppression of TNF-α genes (Gao et. al., 2002, 2004; Yamada, 1995; Yim et. al., 2005). 
However, the beneficial effects can not be only attributed to the size of the polymer. The 
different effect obtained with the strains CRL 1190, CRL 804 and CRL 638 evinced that the 
phenomenon is strongly strain-dependent and complex. 
Whey proteins as α-lactalbumin would also have gastroprotector effect (Matsumoto et. al., 
2001; Rosaneli et. al., 2004; Ushida et. al., 2003, 2007); so, the interaction of EPS-producing 
LAB or the EPS with milk proteins may be a key factor in gastroprotection. Studies on the 
interaction between EPS and milk proteins is complex since EPS are gradually produced 
during fermentation, and the characteristics of the proteins such as charge and 
hydrophobicity may change during fermentation and consequently the interaction between 
them. The EPSs bind water and increase the moisture in the non-fat portion, interfere with 
protein-protein interactions reducing the rigidity of the protein network, and increase the 
viscosity of the serum phase (Hassan, 2008). Similar research was carried out by Ayala-
Hernandez et. al. (2008) who studied the interaction between milk proteins and the EPS 
produced by Lactococcus lactis ssp. cremoris using SEM techniques. They observed that EPS 
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molecules clearly interact not only with caseins but also with whey proteins and play an 
active role in the formation of the aggregates. 
Considering these statements, it is assumed that in fermented milks, e.g., FM-1190, the LAB 
strains and the EPS together with the milk and whey proteins perform a stable three-
dimensional complex network, which is attached to the gastric mucosa preferably to the 
mucus layer, when it is administered to animals. Thus, the EPS could interact with the 
mucosal tissue exerting an inmunomodulador effect, thus avoiding inflammation and or 
making the mucus barrier stronger, which could also affect H. pylori adhesion. The mode of 
action of probiotic LAB strains and their EPS in gastritis has not yet been completely elucidated. 
4. Conclusion 
Gastritis is the most common illness associated to the stomach, and it is the beginning of 
different complication that led to ulcers and, in the worst case, gastric cancer. The disease is 
due to different causes as an imbalanced diet, intake of aggressive agents, or stress process 
(related to neurological condition) which is very common nowadays due to the population 
rhythm of life. However, the most aggressive case is due to H. pylori infection. Allopathic 
treatment of gastritis includes different conventional drugs acting as inhibitors of the proton 
pump and of the acid gastric production, thus helping the stomach to balance the acid 
condition when there is an inflammation, infection or injury. The increase in gastric pH is a 
necessary condition to stop autodigestive processes and support mucosal healing in the 
extreme environment of the gastric lumen; this effect is mainly required in the treatment of 
peptic ulcer. Other drugs are also used, which exert different effects on the gastric mucosa 
tissue to alleviate the inflamed condition, e.g., by stimulation of the mucus synthesis, 
inhibition of the stomach motility, or by displaying anti-H. pylori effects, among other 
properties. The disadvantages of employing these drugs for long periods, such as ranitidine, 
OPZ and derivates, and antibiotics in the case of H. pylori infection, is that many of them 
could have side effects.  
Medicinal plants and their effect in different kind of diseases, on the basis of ancient 
knowledge and supported by scientific evidences, emerge as an alternative therapy to cure 
or prevent gastric disorders. The beneficial effects are mainly related to anti-inflammatory 
activity and the ability to maintain a balance in the mucus barrier and mucosal renovation. 
Phenolic compounds, polysaccharides and derivates in different combinations are mainly 
involved in gastric protection, effect associated in some cases to modulation of the immune 
system (cytokine regulation) and mucus stimulation.  
Probiotic lactic acid bacteria and probiotic foods, which beneficial effects on the gut health 
are strongly supported by scientific evidences, also appear as a novel and promising bio-
alternative for gastritis treatment. Recent evidences indicate that some exopolysaccharide 
(EPS)-producing lactic acid bacteria are able to regulate and to revert the gastritis process 
prompted by NSAIDs, a property that is mainly related to the EPS produced by specific 
strains. The biopolymers could also interact with H. pylori and inhibit its adhesion to mucus 
barrier thus avoiding the infection process. The mode of action of probiotics and their EPS, 
which involves modulation of the immune system, increase in gastric pH, and stimulation 
of mucus production, among other cascade reactions, is under study. 
Considering the beneficial effects of these bio-treatments in gastritis processes, it would be 
advisable to include them as adjunct in conventional treatments programs to reduce the side 
effect derived from the intake of drugs during long periods.  
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